For stages II and III CRC patients with 5-FU-based adjuvant chemotherapy, Perez-Carbonell et al. [175] observed that IGFBP3 hypomethylation was associated with longer overall survival and disease-free survival. Here, IGFBP3 is linked to colorectal carcinoma.